Dynamic FIB-4 Score Changes and HCC Risk in Patients with MASLD and Elevated Liver Enzymes: A Nationwide Cohort Study
Authors:
- Yee Hui YeoYYYee Hui Yeo
- Hsiu J. HoHHHsiu J. Ho
- Tsai-Wei HuangTHTsai-Wei Huang
- Teng-Yu LeeTLTeng-Yu Lee
- Ju Dong YangJYJu Dong Yang
- George CholankerilGCGeorge Cholankeril
- Chien-Jen ChenCCChien-Jen Chen
- Hawi-I. YangHYHawi-I. Yang
- Chuen-Fei ChenCCChuen-Fei Chen
- Hung-Chuen ChangHCHung-Chuen Chang
- Chun-Ying WuCWChun-Ying Wu
Open Access
- 12 January 2026
- journal article
- Published by S. Karger AG in Liver Cancer
- p. 1-12
Abstract
Introduction: Hepatocellular carcinoma (HCC) can develop in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) without cirrhosis, especially in those with elevated liver enzymes. However, there is currently no low-cost, scalable screening tool for this population. To address this need, we investigated the association between serial changes in FIB-4 (fibrosis-4) scores over a 3-year period and the risk of developing HCC in a large, diverse cohort of patients with MASLD without cirrhosis. Methods: This study utilized a nationwide cohort from the National Health Insurance Research Database (NHIRD), including 810,698 patients with MASLD who had demographic and laboratory data at baseline and at least 3 years of follow-up. FIB-4 scores were analyzed to assess transitions between low-risk (2.67) categories over time. Competing risks for HCC and mortality were modeled to estimate the sub-distribution hazard ratios (SHRs). Results: Changes in FIB-4 scores over time provided superior predictive accuracy compared to one-time measurement. Individuals with persistent high FIB-4 (high-to-high group) had a 14-fold higher risk of developing HCC (adjusted SHR [aSHR] 13.91, 95% CI: 11.94–16.20) compared to those with stably low FIB-4 (low-to-low group), while those with improved scores (high-to-low and high-to-indeterminate groups) had a lower risk compared to the high-to-high group. Worsening FIB-4 scores, as shown in the low-to-indeterminate group (aSHR 2.22, 95% CI: 1.93–2.57 or the low-to-high group (aSHR 4.75, 95% CI: 3.38–6.68), were associated with progressively increased risks of HCC compared to the low-to-low group. In contrast, when compared to the high-to-high group, those with improved FIB-4 scores, including the high-to-indeterminate group (aSHR 0.41, 95% CI: 0.35–0.48) and the high-to-low group (aSHR 0.25, 95% CI: 0.15–0.42), exhibited reduced HCC risks. Conclusion: Serial FIB-4 measurements offer greater accuracy in identifying individuals at high risk for HCC in non-cirrhotic MASLD Asians with elevated liver enzymes, with HCC surveillance warranted in high-risk groups.Keywords
This publication has 41 references indexed in Scilit:
- Liver fibrosis scores predict liver disease mortality in the United States populationHepatology, 2017
- The Fine–Gray model under interval censored competing risks dataJournal of Multivariate Analysis, 2016
- Temporal Trends of Nonalcoholic Fatty Liver Disease–Related Hepatocellular Carcinoma in the Veteran Affairs PopulationClinical Gastroenterology and Hepatology, 2015
- Validation of Acute Myocardial Infarction Cases in the National Health Insurance Research Database in TaiwanJournal of Epidemiology, 2014
- Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver diseaseHepatology, 2011
- Validation of the national health insurance research database with ischemic stroke cases in TaiwanPharmacoepidemiology and Drug Safety, 2010
- Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2009
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- Accuracy of diabetes diagnosis in health insurance claims data in Taiwan.2005
- Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical backgroundJournal of Gastroenterology, 2003